OraSure Technologies, Inc.
http://www.orasure.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OraSure Technologies, Inc.
BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
BIO Notebook: US FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include user fees potentially supporting the FDA's AI ambitions, the evolving pros and cons of partnering, and J&J's view on dealmaking in 2024.
Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak
South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.
Will The Dark Tunnel For Korean Biopharmas End In 2023?
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
Company Information
- Industry
- Biotechnology
- Distributors
- Services
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Drug Monitoring
- Urine-based Testing
- Other Names / Subsidiaries
-
- Corebiome
- Diversigen
- DNA Genotek
- Novosanis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice